Novartis returns to the discount aisle, buys Xoma's failed PhIII drug for $31M
Two years after a Phase III flop for its lead drug gevokizumab put Xoma $XOMA under a dark cloud, Novartis has stepped up to buy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
